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SenescenceCysteine-rich protein 61 (CCN1/CYR61) is a CCN (CYR61, CTGF (connective tissue growth factor), and NOV
(Nephroblastoma overexpressed gene)) family matricellular protein comprising six secreted CCN proteins in
mammals. CCN1/CYR61 expression is associated with inﬂammation and injury repair. Recent studies show
that CCN1/CYR61 limits ﬁbrosis in models of cutaneous wound healing by inducing cellular senescence in
myoﬁbroblasts of the granulation tissuewhich thereby transforms into an extracellularmatrix-degrading pheno-
type. We here investigate CCN1/CYR61 expression in primary proﬁbrogenic liver cells (i.e., hepatic stellate cells
and periportalmyoﬁbroblasts) and found an increase of CCN1/CYR61 expression during early activation of hepat-
ic stellate cells that declines in fully transdifferentiated myoﬁbroblasts. By contrast, CCN1/CYR61 levels found in
primary parenchymal liver cells (i.e., hepatocytes)were relatively low compared to the levels exhibited inhepatic
stellate cells and portal myoﬁbroblasts. In models of ongoing liver ﬁbrogenesis, elevated levels of CCN1/CYR61
were particularly noticed during early periods of insult, while expression declined during prolonged phases of
ﬁbrogenesis. We generated an adenovirus type 5 encoding CCN1/CYR61 (i.e., Ad5-CMV-CCN1/CYR61) and
overexpressed CCN1/CYR61 in primary portal myoﬁbroblasts. Interestingly, overexpressed CCN1/CYR61 signiﬁ-
cantly inhibited production of collagen type I at both mRNA and protein levels as evidenced by quantitative real-
time polymerase chain reaction, Western blot and immunocytochemistry. CCN1/CYR61 further induces produc-
tion of reactive oxygen species (ROS) leading to dose-dependent cellular senescence and apoptosis. Additionally,
we demonstrate that CCN1/CYR61 attenuates TGF-β signaling by scavenging TGF-β thereby mitigating in vivo
liver ﬁbrogenesis in a bile duct ligation model. Conclusion: In line with dermal ﬁbrosis and scar formation,
CCN1/CYR61 is involved in liver injury repair and tissue remodeling. CCN1/CYR61 gene transfer into extracellular
matrix-producing liver cells is therefore potentially beneﬁcial in liver ﬁbrotic therapy.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Cysteine-rich protein 61 (CCN1/CYR61) is a CCN familymatricellular
protein comprising six secreted CCN proteins in mammals. The CCN
acronym is derived from the ﬁrst three identiﬁed members of this
family, CYR61, CTGF (connective tissue growth factor), and NOVile duct ligation; β-Gal, β-galac-
tracellular matrix; HSC, hepatic
s); PDGF-BB, platelet-derived
or receptor type β; pMF, portal
transforming growth factor-β1;
PCR, quantitative real-time PCR
istry and Pathobiochemistry,
. Tel.: +49 241 8088683; fax:
am-Kamphorst),
ights reserved.(Nephroblastoma overexpressed gene) [1,2]. CCN1/CYR61 is an im-
portant regulator of inﬂammation and wound repair. It is strongly
expressed inmyoﬁbroblasts (MFB) of granulation tissue and controls
ﬁbrosis through cellular senescence. MFB are recruited in cutaneous
wound healing to form the granulation tissue where they proliferate
and rapidly synthesize extracellular matrix (ECM) components to
provide tissue integrity during repair. At later stages of wound healing,
MFB are driven into senescence by CCN1/CYR61, whereupon they
transform into an ECM-degrading phenotype, thus limiting ﬁbrosis
[1,3]. Effectively, CCN1/CYR61 functions as an anti-ﬁbrotic molecular
switch that converts ECM-producing MFB into ECM-degrading senes-
cent cells [4,6].
The CCN1/CYR61-induced senescence switch occurs at later stages
ofwoundhealing, exerting a self-limiting effect on the synthesis and de-
position of ECM byMFB in several ways. First, senescent MFB no longer
proliferate, thereby curbing the number of ECM-producing cells. Sec-
ond, senescent cells express the anti-ﬁbrotic senescence-associated
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loproteinases and reduced expression of collagen, leading to matrix
degradation. Third, senescent cells are cleared by natural killer cells,
thus accelerating wound resolution. Hence, CCN1/CYR61 turns the
ECM synthesizing MFB themselves into ECM-degrading senescent
cells, thereby imposing a self-limiting effect on ﬁbrogenesis and pro-
moting wound resolution [4,6].
Knock-in mice expressing a CCN1/CYR61 mutant that is unable to
bind the α6β1-heparan sulfate proteoglycans are defective for senes-
cence induction [7]. Consequently, senescent cells do not accumulate
in the granulation tissue duringwoundhealing, resulting in exacerbated
ﬁbrosis. Topical application of puriﬁed recombinant CCN1/CYR61 pro-
tein to cutaneous wounds however does reverse these defects, further
underlining the critical role of CCN1/CYR61 in controlling MFB senes-
cence to limit ﬁbrosis [5].
Liver ﬁbrosis results from wound-healing responses characterized
by the accumulation of ECM following injury [8,9]. If the insult is acute
or self-limited, the liver architecture restores to its normal composition,
but if the injury is sustained, chronic inﬂammation and accumulation of
ECMwill persist and lead to progressive substitution of liver parenchy-
ma through scar tissue formation.
Recent studies showed senescent hepatic stellate cells (HSC) to ac-
cumulate in carbon tetrachloride (CCl4)-induced liver damage and
dampen liver ﬁbrosis through expression of anti-ﬁbrotic proteins,
suggesting that senescent cells may arise to limit ﬁbrosis during tissue
repair, but this phenomenon has not yet been examined beyond
CCl4-induced liver injury. In mice lacking key senescence regulators,
HSC continue to proliferate, leading to excessive liver ﬁbrosis and
scar formation [10].
In addition to cutaneous wound healing, CCN1/CYR61 expression is
elevated in remodeling cardiomyocytes after myocardial infarctions
[11], during vascular injury [12], and in the long bones during fracture
repair, speciﬁcally in proliferating chondrocytes and osteoblasts [13].
In line, it was demonstrated that CCN1/CYR61 blockage by antibodies
inhibits bone fracture healing in mice [14]. In kidney, this CCN protein
is expressed in podocytes in normal adult and embryonic glomeruli,
but CCN1/CYR61 expression is strongly decreased in IgA nephropathy,
diabetic nephropathy and membranous nephropathy, particularly in
diseased kidneys with severe mesangial expansion [15]. CCN1/CYR61
impaired functioning therefore may contribute to the progression of
glomerular disease with mesangial expansion. The precise role of
CCN1/CYR61 in liver ﬁbrogenesis still requires further research.
We here investigate CCN1/CYR61 gene expression in different pri-
mary liver cells, and liver tissue from animals undergoing bile duct
ligation (BDL) and CCl4 treatment, using quantitative real-time PCR
(qRT-PCR), Western blotting, and immunohistochemistry to query the
effects of CCN1/CYR61. CCN1/CYR61 protein was further overexpressed
in cirrhotic fat storing cell lines CFSC, portal myoﬁbroblasts (pMF) and
HSC, using plasmid transfection and adenoviral gene expression. We
showed CCN1/CYR61 to induce cellular apoptosis in CFSC, pMF and
HSC and reduce expression of ﬁbrotic markers, including collagen type
I α1 (col1α1) and α-smooth muscle actin (α-SMA). CCN1/CYR61 in-
duces apoptosis through induction of reactive oxygen species (ROS) as
conﬁrmed by elevated levels of cleaved caspase, caspase activity and
terminal transferase dUTP nick end-labeling (TUNEL) assay. Moreover,
we demonstrate that CCN1/CYR61 sequesters TGF-β, resulting in
decreased TGF-β signaling and ﬁbrogenesis while Ad5-CMV-
CCN1/CYR61 in vivo mitigated liver ﬁbrosis in a bile duct ligation
model.
2. Material and methods
2.1. Liver cells and cell lines
pMFwere isolated frommale Sprague–Dawley rats with a weight of
500–750 g as described previously [16]. Rats were anesthetized withketamine and xylazine following exploratory laparotomy and the liver
perfused in situ with collagenase (300 mg/l, Worthington, Lakewood,
NJ). Hepatic hilum was removed manually from dissociated parenchy-
mal elements and digested serially with a 0.25% pronase (Merck,
Darmstadt, Germany) and 0.1% hyaluronidase (Sigma, Taufkirchen,
Germany) solution and cell suspensions ﬁltered through a 100 μm-
pore mesh. The resulting suspension of non-parenchymal cells was
plated for 24 h in Dulbecco's modiﬁed medium/F-12 with 3% fetal
calf serum (FCS) and then supplemented to 10% FCS. Upon culturing,
portal ﬁbroblasts did differentiate into pMF and showedmicroscopic
appearance of spindle morphology and were positive for ﬁbulin-2
[17] andα-SMA and negative for desmin [18]. Primary HSC were iso-
lated from male Sprague–Dawley rats through density gradient cen-
trifugation technique and cultured as described [19,20]. MFB were
obtained by sub-cultivation of HSC at day 7 of initial culturing.
2.2. RNA isolation, cDNA synthesis, and qRT-PCR
Total RNA from HSC/MFB and immortalized rat CFSC-2G cells [21]
was isolated through QIAzol lysis reagent and RNeasyMini kits (Qiagen,
Hilden, Germany) according to manufacturer's instructions. RNA from
liver was isolated according to a guanidine thiocyanate/CsCl method
[22], followed by DNAse digestion and subsequent RNeasy clean up.
Primers for ampliﬁcation were selected from sequences deposited in
the GenBank database (Table A1) using the Primer Express software
(Applied Biosystems Invitrogen, Darmstadt, Germany). First-strand
cDNA was synthesized from 1 to 2 μg RNA in 20 μl volume using Su-
perScript™ II reverse transcriptase and random hexamer primers
(Invitrogen). To allow semi-quantitative analysis of mRNA expres-
sion, cDNAs were ampliﬁed at low cycle numbers in the range of lin-
ear ampliﬁcation. For quantitative real-time PCR, cDNA derived from
25 ng RNA was ampliﬁed in 25 μl volume using qPCR Core Kits
(Eurogentec, Cologne, Germany). PCR conditions were set to 50 °C
for 2 min, 40 cycles at 95 °C for 15 s and 60 °C for 1 min. All TaqMan
primers used in this study are given in Table A1. RNA normalization
was achieved through TaqMan Ribosomal RNA Control Reagents
(Applied Biosystems) designed for 18S ribosomal RNA (rRNA)
detection.
2.3. Overexpression of CCN1/CYR61 in CFSC
For transient overexpression of CCN1/CYR61, we used the expres-
sion plasmid IRAKp961O1410Q (imaGenes, Berlin, Germany) contain-
ing full-length cDNA of murine CCN1/CYR61. For transfection, cells
were seeded in 6-well plates one day before transfection in Dulbecco's
Modiﬁed Eagle Medium (DMEM) containing 10% FCS, 4 mM L-gluta-
mine, 100 IU/ml penicillin, and 100 μg/ml streptomycin, while non-
essential amino acidswere added for CFSC. Prior to transfection, theme-
dium was renewed and cells were transfected with 2 μg vector each
using the Mirus transfection reagent (Mirus, VWR International
GmbH, Darmstadt, Germany) in accordance with manufacturer's
instructions.
2.4. Cloning of the adenoviral expression vector AdEasy-1-CMV-
mCCN1/mCYR61
The full-length cDNA of murine CCN1/CYR61 of clone
IRAKp961O1410Qwas released by a KpnI/NotI cut and cloned into ade-
noviral shuttle vector pShuttle-CMV that was cut by the same enzymes
resulting in vector pShuttle-CMV-mCCN1/mCYR61. The integrity of this
vector was proven by sequencing (Fig. A1) and restriction site analysis.
Thereafter, the shuttle vectorwas linearized by digestwith PmeI and the
CMV-mCCN1/mCYR61 expression cassette was transferred by homolo-
gous recombination in BJ5183 cells into the AdEasy-1 backbone vector
using standard protocols. Two individual recombinants of AdEasy1-
CMV-mCCN1/mCYR61 (i.e. Ad5-CMV-CCN1-2 and Ad5-CMV-CCN1-8)
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cation protocol using CsCl centrifugation and the Adeno-X Maxi Puriﬁ-
cation kit (Clontech, Mountain View, CA).
2.5. Adenoviral gene transfer into primary pMF
Primary pMF were used up to the 4th passage. For infection, they
were incubated for 24 h with 2 × 109 virions/ml of Ad5-CMV-CCN1 or
the viral control Ad5-CMV-Luc expressing luciferase. Following adeno-
viral transduction, themediumwas changed and cells weremaintained
in DMEM/F12 under normal growth condition (10% FCS) for indicated
periods following assessment of CCN1/CYR61 induced cellular senes-
cence, apoptosis and antiﬁbrotic effects.
2.6. SDS-PAGE and Western blot analysis
Cell and tissue lysates were prepared using RIPA buffer containing
20 mM Tris–HCl (pH 7.2), 150 mM NaCl, 2% (w/v) NP-40, 0.1% (w/v)
SDS, 0.5% (w/v) sodium deoxycholate and the Complete™-mixture of
proteinase inhibitors (Roche, Mannheim, Germany). Equal amounts ofF
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Fig. 1. Expression analysis of CCN1/CYR61 in primary cultured hepatic cell subpopulations and e
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(sc-13100), α-SMA, LCN2 and with β-actin as loading control. (E) Immunohistochemistry
positive staining in nonparenchymal cells (black arrows). IgG served as a negative control.cellular protein extracts or supernatants were diluted with Nu-PAGE™
LDS electrophoresis sample buffer with DTT as reducing agent, heated
at 95 °C for 10 min, and separated in 4–12% Bis–Tris gradient gels and
10% Bis–Tris gels, using MOPS or MES running buffer (Invitrogen). Pro-
teins were electroblotted on nitrocellulosemembranes, and equal load-
ing was shown in Ponceau S stain. Subsequently, non-speciﬁc binding
sites were blocked in TBS containing 5% (w/v) non-fat milk powder.
All antibodies (Table A2) were diluted in 2.5% (w/v) non-fat milk pow-
der in Tris-buffered saline. Primary antibodies were visualized using
horseradish peroxidase conjugated anti-mouse, anti-rabbit or anti-
goat IgG (Santa Cruz Biotech, Santa Cruz, CA) and the SuperSignal
chemiluminescent substrate (Pierce, Bonn, Germany).2.7. Animal experiments and specimen collection
All animal protocols were in compliance with the guidelines for an-
imal care approved by the German Animal Care Committee. Sprague–
Dawley rats were subjected to BDL as described previously [23], and
sacriﬁced at indicated time points. Liver specimen was snap frozen in
liquid nitrogen for protein and RNA isolation or ﬁxed in 4% buffered400x
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Dawley rats weighing 180–200 g received intraperitoneal injections of
1 ml/kg of CCl4 in an equal volume of mineral oil twice weekly for up
to 12 weeks following established protocols [24].2.8. Immunohistochemistry
Liver tissue sections were treated as described before [24]. For
CCN1/CYR61 detection, we applied a sheep anti-mouse CCN1/CCYR61
antibody (AF4055; R&D Systems, Wiesbaden, Germany) overnight.
Liver slides were incubated with biotinylated secondary antibodies
(DAKO, Hamburg, Germany) and developed with the Vectastain ABC-
Elite reagent (Vector Laboratories, Eching, Germany) and peroxidase
substrate 3,3′-diaminobenzidine substrate (Sigma).2.9. Fluorescent immunocytochemistry
pMF cultured on coverslips were ﬁxed at indicated time points with
4% paraformaldehyde in PBS for 15 min at room temperature, followed
by a 5 min permeabilization step with 0.3% TritonX-100 and 0.1%
sodium citrate (pH 6) on ice. Coverslips were then blocked with 50%
FCS, 1% BSA and 0.025% Tween 20 in PBS for 30 min at 37 °C, followed
by 4 °C overnight incubation with primary antibodies. Subsequently,
the Alexa Fluor® conjugate secondary antibodies were applied for 1 h
at room temperature and the nuclei were counterstained with
4′,6-diamidino-2-phenylindole (DAPI). Finally, the coverslips were
mounted on glass slides and analyzed by ﬂuorescence microscopy.
This protocol was also applied for ﬂuorescence double staining of
liver cryosections.Fibulin-2 -SM
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Fig. 2. Characteristics of primary pMF in culture. (A) Immunohistochemistry of primary pMF cu
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around the nucleus in cultured differentiated pMF. Cells expressing high levels of CCN1/CYR612.10. Detection of cellular senescence
To measure cellular senescence, the activity of β-galactosidase
(β-Gal) was measured at pH 6 using the Senescence β-Galactosidase
Staining Kit (#9860) obtained from Cell Signaling Technology (NEB,
Frankfurt, Germany), essentially following manufacturer's instructions.
2.11. Terminal transferase dUTP nick end-labeling assay (TUNEL)
For DNA fragmentation detection resulting from apoptotic signaling
cascades, we used the In Situ Cell Death Detection Kit Fluorescein
(Roche) according to manufacturer's instructions. The presence of
nicks in the DNA was identiﬁed by terminal deoxynucleotidyl transfer-
ase (TdT), an enzyme that catalyzes the addition of labeled dUTPs.
Cultured pMFonglass coverslipswere analyzed byﬂuorescencemicros-
copy for direct ﬂuorescein. For positive control staining, the specimens
were digested with DNAse.
2.12. Reactive oxygen species (ROS) detection
The formation of ROS was analyzed with the Reactive Oxygen Spe-
cies Detection Reagents (Invitrogen). In this assay system, the carboxyl
derivative of ﬂuorescein (10 μMCM-H2DCFDA, Invitrogen) was applied
as cell-permeated indicator dye for ROS in cultured pMF on glass slides
for 30 min. The chemically reduced and acetylated forms of 2′,7′-
dichloroﬂuorescein (DCF) and calcein are non-ﬂuorescent until the ac-
etate groups are removed by intracellular esterases and oxidation oc-
curs within the cell. Esterase cleavage of the lipophilic blocking groups
yields a charged form of the dye that can be visualized by ﬂuorescence
microscopy. For ROS in situ quantitative analysis, cells were cultured in
96 well plates and the ﬂuorescence measured by microplate readerA
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notably showed reduced α-SMA expression.
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values normalized with cellular DNA.
2.13. Luciferase reporter gene assay
Experiments were performed in 6-well plates. Conﬂuent pMF cells
in 4% FCS were transduced with Ad5-(CAGA)12-MLP-Luc followed by
Ad5-CMV-CCN1 12 h later. Cells were starved for 16 h in medium con-
taining 0.5% FCS and renewed with 0.2% FCS and 1 mg/ml BSA before
stimulation with TGF-β at indicated doses for 12 h. Cell extracts were
prepared in 350 μl of passive lysis buffer (Promega), and 20 μl was
used for luciferase measurements. All experiments were conducted in
triplicate.
2.14. CCN1/CYR61-Fc chimera/TGF-β1 co-immunoprecipitation
Samples for co-immunoprecipitation (co-IP) containing recombi-
nant human CCN1/CYR61-Fc chimera (#4055-CR-050) and recombi-
nant human TGF-β1 (240-B-002) were obtained from R&D Systems,
and set up in a total volume of 400 μl PBS, rotated for 6 h at 4 °C, then
20 μl Protein-G PLUS agarose beads equilibrated in PBS (Santa Cruz Bio-
tech, Santa Cruz, CA) were added and the mixture rotated overnight at
4 °C. Aliquots (30 μl) were taken without further treatment (−Protein
G precipitation) and the remaining 370 μl was subjected to standardCol I 1
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
-SMA
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Ad5-CCN1 Ad5-Luccontrol
Co
l I
CC
N1
/C
YR
61
D
A
PI
M
er
ge
neg. coC
A
* *
* * ** *
24 h 48 h 72 h 24 h 48 h
α α
Fig. 3.Ad5-CMV-CCN1 infection induces reduced expression of collagen type I andα-SMA in pM
I and α-SMAmRNA upon transduction with Ad5-CMV-CCN1. (B) Western blot analysis conﬁrm
was onlymarginally affected. ß-actin served as loading control. (C) Immunocytochemistry doub
Ad5-CMV-CCN1 transduction showing Ad5-CMV-CCN1 to signiﬁcantly inhibit collagen type I e
trol. (D) Immunocytochemistry double staining of CCN1/CYR61 (green) and α-SMA (red) of ea
efﬁciently inhibit α-SMA expression.Protein G precipitation (+Protein G precipitation). Protein G beads
were collected by brief centrifugation and washed three times in ice
cold PBS. Samples were run on a Pre-Cast NUPAGE 4–12% polyacryl-
amide gel under reducing conditions with MES running buffer
(Invitrogen, Life Technologies, Darmstadt, Germany). Detection of
TGF-β1 was achieved with antibody CS#3711 (Cell Signaling, New
England Biolabs, Frankfurt, Germany) and CCN1/CYR61-Fc chimera
was detected using an afﬁnity puriﬁed polyclonal sheep antibody
(AF4055) directed against murine CCN1/CYR61 (R&D Systems). Re-
combinant CCN1/CYR61-Fc chimera and TGF-β1, not subjected to
any further treatment, served as Western blot controls. A recombi-
nant fusion protein harboring the platelet-derived growth factor
receptor type β and the Fc part served as a further control in this
set of experiments. The construction and puriﬁcation of this pro-
tein chimera was reported in detail elsewhere [25].2.15. Statistics
Data are expressed as mean ± standard deviation (SD). Means of
different groups were compared using 1-way analysis of variance. Sta-
tistical analysis was performed using the unpaired Student's t test. Prob-
ability values of less than 0.05, 0.01 and 0.001 were considered as
statistically signiﬁcant and marked with “*”, “**” and “***”.co
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3.1. CCN1/CYR61 expression in isolated primary liver cells
In ﬁbrotic livers, HSC and pMF are considered themain producers of
ECM [8,9]. In culture, primary HSC get activated and transdifferentiate
in a time-dependent manner from a quiescent phenotype into a
proliferative active contractile phenotype (i.e., MFB). We used
qRT-PCR and Western blot to analyze CCN1/CYR61 expression dur-
ing cellular activation and transdifferentiation, both revealing a dra-
matic CCN1/CYR61 increase during initial HSC activation, followed
by a subsequent decline in fully transdifferentiated MFB and comparable
to the CCN1/CYR61 levels in passaged pMF. By contrast, CCN1/CYR61A
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was relatively minor compared to HSC, MFB and pMF, while lipocalin 2
(LCN2), known to be induced during prolonged culturing of hepatocyte,
showed a marked upregulation (Fig. 1A, B). Immunoﬂuorescent double
staining of GFAP, a marker of HSC, and CCN1/CYR61 was conﬁrmed in
primary HSC that were cultured for one day after isolation (Fig. 1C).
3.2. Expression of CCN1/CYR61 in experimental ﬁbrotic models
Next, we investigated CCN1/CYR61 expression in two different
in vivo models of hepatic ﬁbrogenesis using qRT-PCR of liver RNA
samples and Western blot analysis of protein extracts isolated from
rats subjected to BDL surgery and CCl4 treatment. In agreement withYR61
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CCN1/CYR61 upon initial application, decreasing following long-
term application and liver ﬁbrosis (Fig. A2A and B). CCN1/CYR61 immu-
nohistochemistry of specimens taken from rat livers subjected to BDL
and CCl4 showed positive staining in non-parenchymal cells, i.e. HSC
and pMF (Fig. 1F and Fig. A2C). Immunoﬂuorescent double staining
showed high background in parenchymal cells, with a stronger positive
signal in perisinusoidal areas andminimal co-localization with collagen
type I positive cells (Fig. A2D).3.3. Characteristics of isolated primary pMF
Immunocytochemistry of cultured primary pMF showed positive
staining of ﬁbulin-2, a speciﬁc marker of this hepatic cell subpopulation
(Fig. 2A). Compared to its HSC counterpart, pMF do express α-SMA but
are negative for desmin, as conﬁrmed by both immunohistochemistry
and Western blot analysis (Fig. 2B and C). In early periods of culturing,
CCN1/CYR61was found to localizemainly in the endoplasmic reticulum
around the nucleus, while more differentiated pMF expressed overall
lower levels of CCN1/CYR61, combined with higher levels of α-SMA ﬁl-
ament (Fig. 2D).3.4. Ad5-CMV-CCN1 decreased collagen type I and α-SMA expression in
pMF
Cultured pMF at passage 2 were infected with Ad5-CMV-CCN1 for
24, 48 and 72 h and analyzed for expression of col1α1 and α-SMA by
qRT-PCR. Interestingly, the overexpression of CCN1/CYR61 resulted in
markedly decreased expression of both col1α1 and α-SMA mRNA
(Fig. 3A). Ad5-CMV-CCN1 mediated gene transfer in pMF triggered
very high level expression of CCN1/CYR61 (Fig. 3B) in both cell lysate
and culture supernatant (data not shown). Western blot conﬁrmed
the qRT-PCR analysis, showing overexpression of CCN1/CYR61 to signif-
icantly reduce collagen type I production, with only a marginal impact
of CCN1/CYR61 on α-SMA protein expression (Fig. 3B). Immunohisto-
chemistry also conﬁrmed the overexpression of CCN1/CYR61 in the re-
spective cells and to inhibit col1α1 production (Fig. 3C). Foregoing was
conﬁrmed in Ad5-CMV-CCN1 transduced primary HSC (Fig. A3A) and
plasmid transfected CFSC (Fig. A3B). Interestingly, overexpression of
CCN1/CYR61 through Ad5-CMV-CCN1 in early stage of pMF was able
to inhibit α-SMA expression (Fig. 3D).3.5. Ad5-CMV-CCN1 induced pMF apoptosis
We further foundoverexpression of CCN1/CYR61 in pMF to correlate
with an increase of apoptotic marker proteins such as FAS and cleaved
caspase-3 and -9 (Fig. 4A). Ad5-CMV-CCN1 transduced pMF also
showed a signiﬁcant increase in TUNEL positive cells compared to con-
trol culture or Ad5-CMV-Luc-infected cells (Fig. 4B). Moreover, quanti-
tative values for caspase activity increased signiﬁcantly for all types of
caspases (Fig. 4C), butmore prominent for caspase 9 and 3–7 compared
to caspase 8.3.6. Ad5-CMV-CCN1 induced ROS production and activation of p38 and JNK
in pMF
To test if transient overexpression of CCN1/CYR61 results in elevated
intracellular ROS levels,we performed ROS staining in pMF24h after in-
fection. The transduction of CCN1/CYR61 resulted in a marked increase
of ROS production relative to normal cultures or Ad5-CMV-Luc infected
cells, as conﬁrmed by quantitative analysis (Fig. 5A). Additionally, ade-
noviral infection with Ad5-CMV-CCN1 induced p38 and JNK phosphor-
ylation (Fig. 5B).3.7. Ad5-CMV-CCN1 showed no difference in β-galactosidase (β-Gal)
staining
Passaged cultured pMF in 10% FCS showed senescence innormal cul-
tures including Ad5-CMV-Luc-infected and Ad5-CMV-CCN1-infected
cells (Fig. 5C). Compared to all other culture conditions however, Ad5-
CMV-CCN1 infected pMF showed the highest degree of cell detachment
(Fig. 5C). The levels of p21 representing a marker of cellular senescence
increased slightly in Ad5-CMV-CCN1 transduced pMF cells (Fig. 5B). In-
terestingly, Ad5-CMV-CCN1 transduced pMF showed marked nuclear
localization of p21 with decreased collagen type I expression (Fig. 5D).
3.8. CCN1 protein and Ad5-CMV-CCN1 conditioned medium attenuated
collagen type I expression through cellular senescence
pMF incubated with different doses of CCN1-Fc protein in 0.5% FCS
for 96 h or in conditioned media taken from Ad5-CMV-CCN1 infected
pMF were analyzed for CCN1/CYR61 protein and collagen type I
(Fig. 6). Recombinant CCN1-Fc and conditioned medium reduced colla-
gen type I expression in a dose-dependent manner (Fig. 6A, B, D). CCN1
protein induced phosphorylation of p65 and LCN2 expression with de-
creased levels of cleaved caspase 3. Several cellular senescencemarkers,
including pp53, p21 and p16 were upregulated while showing a de-
creased hyperphosphorylated form of Rb (Fig. 6B). β-Gal stain was pos-
itive in normal cultures, but more prominent in pMF incubated with
CCN1-Fc protein (Fig. 6C). Ad5-CMV-CCN1 infected pMF conditioned
media showed the same effects as the CCN1-Fc chimera, but the condi-
tionedmedia contained higher levels of CCN1 protein (data not shown)
resulting in slightly increased caspase 3 cleavage, as conﬁrmed byWest-
ern blot and quantitative caspase assay (Fig. 6D and E).
3.9. CCN1 attenuates TGF-β signaling through physically interacting with
TGF-β
Ad5-CMV-CCN1-infected cells showed a dramatical decrease in col-
lagen type I expression. Since TGF-β is the most prominent growth
factor in collagen I production, we next investigated the effects of
CCN1 on TGF-β signaling in pMF and found both Ad5-CMV-CCN1
expressed and recombinant CCN1 protein to attenuate Smad protein
phosphorylation, including pSmad1/5/8, pSmad2 and pSmad3 (Fig. 7A
and B). The luciferase reporter gene assay (CAGA-luciferase) duly con-
ﬁrmed the Western blot results (Fig. 7C). A binding assay of CCN1-Fc
protein and TGF-β following immunoprecipitation of the CCN1-Fc chi-
mera proved the CCN1 protein to bind to TGF-β (Fig. 7D), while an irrel-
evant protein consisting of the extracellular domain of the platelet-
derived growth factor receptor type β and the Fc part was unable to
bind to TGF-β under the chosen experimental conditions.
3.10. Ad5-CMV-CCN1 attenuated liver ﬁbrosis in the BDL model
Since pMF play an essential role in biliary ﬁbrotic models [26,27],
2-week-sham and BDL animals were treated with Ad5-CMV-CCN1
(1 × 1010 virions/animal/week). In this analysis, Ad5-CMV-GFP was
used as the viral vector control. In liver, both adenoviral constructs
effectively transduced parenchymal and non-parenchymal liver
cells (Fig. 8A). The Ad5-CMV-CCN1 treated group showed signiﬁcant
decreased collagen type I and α-SMA levels in Western blot, Sirius
red and immunohistochemistry (Fig. 8B, C, and D). ROS staining in
respective liver sections further showed the occurrence of elevated
concentrations of ROS in animals that received Ad5-CMV-CCN1
(Fig. 8E and F). Moreover, senescence β-galactosidase staining
reﬂected positive signals around portal areas in all BDL livers, with
Ad5-CMV-CCN1 showing the strongest signals (Fig. 8E and F). Fore-
going ﬁndings concur with a recent publication showing that the
CCN1/CYR61 promotes regression of liver ﬁbrosis through induction
of cellular senescence in hepatic myoﬁbroblasts [28]. Additionally,
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911E. Borkham-Kamphorst et al. / Biochimica et Biophysica Acta 1843 (2014) 902–914BDL livers treated with Ad5-CMV-CCN1 showed only TUNEL positive
cells around portal areaswhile controls and Ad5-CMV-GFP infected livers
were mainly positive at the necro-apoptotic region of parenchymal cells.
Furthermore, immunohistochemistry of cleaved caspase 3was positive in
hepatocytes in Ad5-CMV-GFP infected liver sections. By contrast, Ad5-
CMV-CCN1 infected livers showed increased caspase 3 cleavage more
prominently in non-parenchymal cells (Fig. 8E).
4. Discussion
CCN1/CYR61 is a matricellular protein of the CCN family that associ-
ates speciﬁcally with the extracellularmatrix. CCN proteins lack speciﬁc
high-afﬁnity receptors, but do regulate crucial biological processes like
ﬁbrogenesis, by signaling via diverse integrins and proteoglycans.
CCN1/CYR61 enhances cutaneous wound healing through recruitmentFig. 6. CCN1/CYR61 protein and Ad5-CMV-CCN1 conditioned media induced pMF senescence. (
indicated doses of CCN1-Fc protein for 96 h. The recombinant CCN1-Fc protein, endogenous rat C
analysis 10 ng of CCN1-Fc was used as positive control, while the Ponceau S stain served as cont
collagen type I and cleaved caspase 3, but increased pp65, pJNK, pp53, p21 and LCN2. ß-a
hyperphosphorylation of RB protein (lower arrow) that is also induced by incubation with TN
lysate frompMF cultured inAd5-CMV-CCN1 conditionedmedia, showing decreased levels of co
of CCN1were found in the conditionedmedia. ß-actin served as loading control. (E) Quantitativ
media were taken from the parallel normal cultured pMF.of MFB to form the granulation tissue where they proliferate and rap-
idly synthesize ECM components to enforce tissue integrity during
repair.
Similar to cutaneous wound healing, liver ﬁbrosis is a tissue healing
process that recruits MFB from HSC and pMF, depending on the patho-
genesis of the injured liver. We found CCN1/CYR61 upregulation upon
early HSC activation followed by decreasing levels in fully differentiated
MFB, in line with the experimental liver ﬁbrotic models BDL and CCl4
showing CCN1/CYR61 levels to be in reverse to the actual degree of
liver ﬁbrosis (Fig. 1 and Fig. A2). This indicates that CCN1/CYR61 partic-
ipates in tissue repair during the process of inﬂammation and early ﬁ-
brotic tissue formation. By contrast to liver ﬁbrosis, MFB are driven
into senescence by CCN1/CYR61 in later stages of cutaneous wound
healing, whereupon they transform into an ECM-degrading phenotype
and thus limit ﬁbrosis. CCN1/CYR61 therefore functions as an anti-A) Western blot analysis of media (40 μl/lane) taken from pMF that were incubated with
CN1/CYR61, and collagen type I expressionwere detected byWestern blot analysis. In this
rol for equal protein loading. (B)Western blots of cell lysate showing CCN1-Fc to decrease
ctin served as loading control. Please note that the incubation with CCN1-Fc leads to
F-α. (C) β-Gal staining of pMF incubated with CCN1-Fc protein. (D) Western blots of cell
llagen type I,with increased pp65, pJNK, p21, LCN2 and cleaved caspase 3. Signiﬁcant levels
e caspase activity showing signiﬁcant increases in all types of caspases. Control conditioned
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degrading senescent cells, thus imposing a self-limiting control on
ﬁbrogenesis during wound healing [4,6].
During BDL-induced hepatic ﬁbrosis, ﬁbroblasts within the portal
tracts become activated, proliferate and express α-SMA, suggesting
that they are involved in the deposition of ECM components in chole-
static ﬁbrosis [26]. These MFB populations are distinct from HSC as
veriﬁed by marker gene expression analysis [29,17,18], as they speciﬁ-
cally express ﬁbulin-2 and elastin. The majority of MFB in ﬁbrotic
regionswere found to be desmin negative and derived fromportal mes-
enchymal cells rather thanHSC [30], the reasonwhywe did choose pMF
as an in vitro cellular model for anti-ﬁbrotic effects of CCN1/CYR61. We
isolated primary portal ﬁbroblast and tested the anti-ﬁbrotic function of
CCN1/CYR61 in cultured pMF by using Ad5-CMV-CCN1 and found
overexpression of CCN1/CYR61 to inhibit col1α1 and α-SMA produc-
tion (cf. Fig. 3A–C). Inhibition of col1α1 was more prominent than α-
SMA at protein levels as shown by Western blot and immunohisto-
chemistry. Although Ad5-CMV-CCN1 signiﬁcantly inhibited α-SMA
mRNA production, protein expression was reduced only modestly,
which might be due to the long half-life of this protein [31] and the
huge amounts ofα-SMApresent in fully differentiated pMF. By contrast,
during early periods of pMF culturing, immunohistochemistry clearly
showed CCN1/CYR61 over-expression to be sufﬁcient to attenuate α-
SMA production (Fig. 3D). These ﬁndings conﬁrmed the anti-ﬁbrotic
properties of CCN1/CYR61 overexpression through Ad5-CMV-CCN1
transduction.
CCN1/CYR61 induces ﬁbroblast senescence through an integrin-
mediated mechanism, resulting in the expression of anti-ﬁbrotic genes
to dampen ﬁbrosis in cutaneous wound healing [4,6]. Adenoviral
overexpressed CCN1/CYR61 induced pMF apoptosis instead, as evi-
denced by increased levels of cleaved caspase 3 (Fig. 4), themajor effec-
tor caspase in apoptosis, and positive TUNEL staining. Previous reports
claim CCN1/CYR61 to induce ﬁbroblast apoptosis through its adhesion
receptor integrin α6β1 and the heparan sulfate proteoglycan, thus trig-
gering transcription-independent p53 activation of Bax to render cyto-
chrome c release and activation of caspase-9 and -3 [32]. We could
demonstrate that CCN1/CYR61 overexpression in cultured pMF resulted
in increased amounts of cleaved caspase-9 and -3 (Fig. 4A). The caspase
activity showed all caspases to increase, but caspase-9 and caspases 3–7
are more prominent than caspase-8 (Fig. 4B).
We further found cultured passage pMF to acquire a general cellular
senescence as shown by β-galactosidase positive staining in normal cul-
tures, whereas Ad5-CMV-CCN1-infected cells showed both positive β-
galactosidase and cellular detachment from the cell culture dishes
(Fig. 5C), indicating that Ad5-CMV-CCN1 additionally induced pMF
apoptosis. Protein p21 is a cyclin-dependent kinase inhibitor, which is
important in cellular response to genotoxic stress and amajor transcrip-
tional target of p53 protein. In the nucleus it binds to and inhibits the ac-
tivity of cyclin dependent kinases Cdk1 and Cdk2 and blocks the
transition from G1 phase into S phase or from G2 phase into mitosis
after DNA damage, thus enabling repair of damaged DNA [32]. Protein
p21 is further considered as an important protein for induction of repli-
cation senescence as well as stress-induced premature senescence. We
found p53 activation and increased p21 levels in pMF incubated with
CCN1-Fc protein (Fig. 6C) but only slight increases in Ad5-CMV-CCN1Fig. 8.Ad5-CMV-CCN1 attenuated liverﬁbrosis in a BDLmodel. (A) Immunohistochemistry of GF
both parenchymal (hepatocytes) and non-parenchymal cells. In this analysis antibody AF 4055
representative BDL livers showed Ad5-CMV-CCN1 to reduce Sirius red staining and α-SMA c
reﬂecting CCN1 upregulation in BDL liver, but Ad5-CMV-CCN1 treated livers showing higher l
Ad5-CMV-GFP and Ad5-CMV-CCN1 treated animals showed increased caspase-3. LCN2, the ma
control. (D) Collagen type I and α-SMA were quantiﬁed using Boehringer Light Unit (BLU) f
(E) Increased concentrations of ROS (panel 1) and elevated levels of β-Gal activity around peri
the negative control stains, the substrate was omitted. TUNEL andα-SMA co-staining (panel 3) s
in Ad5-CMV-CCN1 infected livers, TUNEL positive cells were limited to non-parenchymal cells
more pronounced stained. While, the immunohistochemistry of cleaved caspase 3 (panel 4)
CCN1 infected livers showed a more positive stain in non-parenchymal cells. (F) Quantiﬁcationtransduced cells. Immunocytochemistry, however, showed p21 nuclear
localization in these cells (Fig. 5D), indicating that CCN1most likely en-
hances pMF senescence through p53 and p21 pathways. In cytoplasm,
p21 exerts anti-apoptotic effects with the ability to bind to and inhibit
caspase 3, as well as the apoptotic kinases ASK1 and JNK [33]. The func-
tion of p21 in response to DNA damage probably depends on the extent
of the damage. In low-level DNAdamage cases such as those induced by
incubation with the CCN1 protein, expression of p21 is increased. It in-
duces cell cycle arrest, and performs anti-apoptotic activities (Fig. 6B).
However, upon extensive DNA damage the amount of p21 protein de-
creases and the cells undergo apoptosis (Figs. 4 and 5B). This dual func-
tionality of p21may explain the simultaneous occurrence of senescence
and apoptosis in cultured cells and whole livers after transduction of
Ad5-CMV-CCN1.
It has been established that CCN1/CYR61 in ECM enables TNF-α to
induce apoptosis without NFκB signaling inhibition [34,35]. We found
that NFκB (pp65) activation is a compensatory cell survival response
during CCN1/CYR61-induced pMF apoptosis (Fig. 4A). Overexpression
of CCN1/CYR61-induced apoptosis is also seen in primary HSC and in
the immortalized hepatic stellate cell line CFSC (Fig. A2A andB) suggest-
ing that it is a general attribute of CCN1/CYR61 in proﬁbrogenic liver
cells. Additionally, CCN1/CYR61-induced ROS formation is required for
CCN1/TNF-α-induced apoptosis through activation of p53 and p38
MAPK, that mediate enhanced cytochrome c release to amplify the
cytotoxicity of TNF-α [36]. Our experiments showed Ad5-CMV-CCN1
infection to markedly induce ROS production that inhibits MAPK phos-
phatase activity resulting in p38 hyperactivation (Fig. 5B), enhance-
ment of mitochondrial cytochrome c release, activation of initial pro-
caspase-9, and activation of the effector caspase 3 (Fig. 4A and B). In
contrast to the context-dependent role of p38, JNK activation appears
generally necessary for TNF-α-induced apoptosis [37]. JNK activation
was clearly evidenced in pMF infected with Ad5-CMV-CCN1.
CCN1/CYR61was strongly expressed at the sites of inﬂammation, in-
jury repair and tissue remodeling and can synergize with FasL and sig-
niﬁcantly enhance FasL-induced apoptosis in ﬁbroblast. CCN1/CYR61
mechanically engages with integrin α6β1 and cell surface heparan sul-
fate proteoglycan, leading to the ROS-dependent hyperactivation of
p38 MAPK in the presence of FasL [38]. We found Ad5-CMV-CCN1-
infection to speciﬁcally induce ROS formation, p38 phosphorylation
and upregulation of Fas in pMF (cf. Figs. 4A, 5A and B), a phenomenon
also observed in hepatocytes transduced with Ad5-CMV-CCN2/CTGF
and Ad5-CMV-CCN3/NOV [39], suggesting that CCN proteins are criti-
cally involved in the excessive formation of free radicals and control of
associated downstream cellular signaling pathways.
Compared to Ad5-CMV-CCN1 or CCN1 plasmid transfection, CCN1-
Fc protein andAd5-CMV-CCN1 conditionedmedia showed some degree
of cellular stress as evidenced by increased LCN2 production, but pMF
were driven into cellular senescence rather than apoptosis. Depending
on the CCN1 protein dosage, the conditioned media contained higher
levels of CCN1 resulting in some degree of cellular apoptosis.
Suppression of collagen type I production from CCN1 was shown in
both Ad5-CMV-CCN1 and CCN1 protein. The CCN protein family is
known to moderate the growth factors and cytokine signaling [40] and
we found CCN1 to attenuate TGF-β signaling through scavenging TGF-
β ligand. Ad5-CMV-CCN1 transduction in our in vivo BDL model didP and CCN1/CYR61 showedAd5-CMV-GFP andAd5-CMV-CCN1 treated livers to transduce
(R&D Systems) was used for CCN1/CYR61 detection. (B) Sirius red and α-SMA IHC of the
ompared to controls. (C) Western blots of 2-week sham-operated and BDL liver lysates
evels of CCN1 resulting in signiﬁcant diminished collagen type I and α-SMA levels, while
rker of liver injury was increased markedly in BDL livers, while β-actin served as loading
rom Lumi-Analyst Image Analysis Software (Roche Diagnostics) normalized to β-actin.
portal areas (panel 2) were found in livers that were transduced with Ad5-CMV-CCN1. In
howed positive areas in both Ad5-CMV-GFP andAd5-CMV-CCN1 infected livers. However,
around portal tracts, while in Ad5-CMV-GFP infected livers the parenchymal areas were
revealed a positive stain in hepatocytes in Ad5-CMV-GFP transduced livers, Ad5-CMV-
of ROS signals, β-Gal stain, and TUNEL staining in sections taken from (E).
914 E. Borkham-Kamphorst et al. / Biochimica et Biophysica Acta 1843 (2014) 902–914transduce both parenchymal and non-parenchymal liver cells, but liver
cell apoptosis wasmainly found in periportal areas, in line with previous
reporting that in bile duct ligation models, myoﬁbroblasts derived from
portal ﬁbroblast disappear during the resolution period by apoptosis
[41]. The attenuation of liver ﬁbrosis from Ad5-CMV-CCN1 therefore
might result from the synergistic effects of cellular senescence, apoptosis
around the portal areas and diminishing TGF-β signaling.
5. Conclusions
Compared to cutaneous wound healing, CCN1/CYR61 overexpres-
sion in liver ﬁbrogenic cells, such as pMF and HSC, promotes tissue
remodeling and active prevention of liver ﬁbrosis though cellular senes-
cence, ﬁbrogenic cell apoptosis and attenuation of TGF-β signaling.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.01.023.
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